Oseltamivir and abnormal behaviors: true or not?

Area of Science:

• Pharmacology
• Epidemiology
• Biostatistics

Background:

• Oseltamivir is a neuraminidase inhibitor used to treat influenza A and B viruses.
• Concerns exist regarding potential neuropsychiatric adverse events, such as hallucinations and delirium, associated with oseltamivir use.
• A large Japanese epidemiological study investigated the link between oseltamivir and adverse behaviors.

Purpose of the Study:

• To re-evaluate the association between oseltamivir intake and adverse behaviors using a corrected analytical method.
• To emphasize the critical role of person-time analysis in cohort studies.

Main Methods:

• Analysis of a large-scale epidemiological study conducted in Japan during the 2006-2007 influenza season.
• Comparison of the original study's flawed analysis with a corrected person-time based analysis.
• Calculation of rate ratio and confidence intervals for adverse behavior occurrence.

Main Results:

• The original study reported no association between oseltamivir and abnormal behaviors.
• A corrected person-time analysis revealed a statistically significant rate ratio of 1.57 (95% CI = 1.34-1.83) for adverse behaviors.
• This indicates a potential increased risk associated with oseltamivir intake.

Conclusions:

• The initial analysis of the Japanese study was methodologically flawed.
• Corrected person-time analysis demonstrates a significant association between oseltamivir use and adverse behaviors.
• This study underscores the necessity of appropriate statistical methods, particularly person-time, in epidemiological research.